NCT00524524View on ClinicalTrials.gov

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Advanced Solid Tumors
Interventions
DRUG

ARQ 501

Weekly IV Infusion; 450 mg/m2

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00524524 - An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter